Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 1961-1973

  Haanstra, Krista G ^a   Hofman, Sam O ^a   Estêvão, Dave M Lopes ^a   Blezer, Erwin L A ^b   Bauer, Jan ^c   Yang, Li Li ^d   Wyant, Tim ^d   Csizmadia, Vilmos ^d   'T Hart, Bert A ^a,e   Fedykx, Eric R ^d  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Medical University of Vienna   (Austria)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4BETA7 INTEGRIN; ANTIBODY; INTEGRIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; PLACEBO; UNCLASSIFIED DRUG; VEDOLIZUMAB; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMYELINATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; FEMALE; HEMISPHERE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSURVEILLANCE; LEUKOCYTE; MALE; MEMORY T LYMPHOCYTE; MULTICENTER STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACODYNAMICS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNITY; CELL MIGRATION INHIBITION; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOLOGIC SURVEILLANCE; INJECTIONS, INTRAVENOUS; INTEGRIN ALPHA4BETA1; MACACA MULATTA; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; ORGAN SPECIFICITY; PLACEBOS; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 84874280106     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202490     Document Type: Article

References (51)

1. von Andrian, U. H., and B. Engelhardt. 2003. Alpha4 integrins as therapeutic targets in autoimmune disease. N. Engl. J. Med. 348: 68-72.
2. Engelhardt, B., and R. M. Ransohoff. 2005. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26: 485-495.
3. Sheridan, B. S., and L. Lefrançois. 2011. Regional and mucosal memory T cells. Nat. Immunol. 12: 485-491.
4. Schweighoffer, T., Y. Tanaka, M. Tidswell, D. J. Erle, K. J. Horgan, G. E. Luce, A. I. Lazarovits, D. Buck, and S. Shaw. 1993. Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with hallmarks of gut-trophism. J. Immunol. 151: 717-729.
5. DeNucci, C. C., A. J. Pagán, J. S. Mitchell, and Y. Shimizu. 2010. Control of alpha4beta7 integrin expression and CD4 T cell homing by the beta1 integrin subunit. J. Immunol. 184: 2458-2467.
6. Erle, D. J., M. J. Briskin, E. C. Butcher, A. Garcia-Pardo, A. I. Lazarovits, and M. Tidswell. 1994. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J. Immunol. 153: 517-528.
7. Rott, L. S., M. J. Briskin, D. P. Andrew, E. L. Berg, and E. C. Butcher. 1996. A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation. J. Immunol. 156: 3727-3736.
8. Baron, J. L., J. A. Madri, N. H. Ruddle, G. Hashim, and C. A. Janeway, Jr. 1993. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177: 57-68.
9. Engelhardt, B., M. Laschinger, M. Schulz, U. Samulowitz, D. Vestweber, and G. Hoch. 1998. The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J. Clin. Invest. 102: 2096-2105.
10. Kent, S. J., S. J. Karlik, C. Cannon, D. K. Hines, T. A. Yednock, L. C. Fritz, and H. C. Horner. 1995. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58: 1-10.
11. Keszthelyi, E., S. Karlik, S. Hyduk, G. P. Rice, G. Gordon, T. Yednock, and H. Horner. 1996. Evidence for a prolonged role of alpha 4 integrin throughout active experimental allergic encephalomyelitis. Neurology 47: 1053-1059.
12. Piraino, P. S., T. A. Yednock, S. B. Freedman, E. K. Messersmith, M. A. Pleiss, and S. J. Karlik. 2005. Suppression of acute experimental allergic encephalomyelitis with a small molecule inhibitor of alpha4 integrin. Mult. Scler. 11: 683-690.
13. Yednock, T. A., C. Cannon, L. C. Fritz, F. Sanchez-Madrid, L. Steinman, and N. Karin. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63-66.
14. Polman, C. H., P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, et al AFFIRM Investigators. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354: 899-910.
15. Coisne, C., W. Mao, and B. Engelhardt. 2009. Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J. Immunol. 182: 5909-5913.
16. Sandborn, W. J., J. F. Colombel, R. Enns, B. G. Feagan, S. B. Hanauer, I. C. Lawrance, R. Panaccione, M. Sanders, S. Schreiber, S. Targan, et al International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. 2005. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353: 1912-1925.
17. Major, E. O. 2010. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61: 35-47.
18. Berger, J. R. 2006. Natalizumab and progressive multifocal leucoencephalopathy. Ann. Rheum. Dis. 65(Suppl 3): iii48-iii53.
19. Tan, C. S., and I. J. Koralnik. 2010. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 9: 425-437.
20. Xavier, R. J., and D. K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
21. Hesterberg, P. E., D. Winsor-Hines, M. J. Briskin, D. Soler-Ferran, C. Merrill, C. R. Mackay, W. Newman, and D. J. Ringler. 1996. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 111: 1373-1380.
22. Soler, D., T. Chapman, L. L. Yang, T. Wyant, R. Egan, and E. R. Fedyk. 2009. The binding specificity and selective antagonism of vedolizumab, an antialpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 330: 864-875.
23. Fedyk, E. R., T. Wyant, L. L. Yang, V. Csizmadia, K. Burke, H. Yang, and V. J. Kadambi. 2012. Exclusive antagonism of the a4 b7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm. Bowel Dis. 18: 2107-2119.
24. Feagan, B. G., G. R. Greenberg, G. Wild, R. N. Fedorak, P. Paré, J. W. McDonald, R. Dubé, A. Cohen, A. H. Steinhart, S. Landau, et al. 2005. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. 352: 2499-2507.
25. Feagan, B. G., G. R. Greenberg, G. Wild, R. N. Fedorak, P. Paré, J. W. McDonald, A. Cohen, A. Bitton, J. Baker, R. Dubé, et al. 2008. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin. Gastroenterol. Hepatol. 6: 1370-1377.
26. Wehner, N. G., C. Gasper, G. Shopp, J. Nelson, K. Draper, S. Parker, and J. Clarke. 2009. Immunotoxicity profile of natalizumab. J. Immunotoxicol. 6: 115-129.
27. Kerlero de Rosbo, N., H. P. Brok, J. Bauer, J. F. Kaye, B. A. 't Hart, and A. Ben- Nun. 2000. Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterisation of immunodominant T- and B-cell epitopes. J. Neuroimmunol. 110: 83-96.
28. 't Hart, B. A., J. Bauer, H. P. Brok, and S. Amor. 2005. Non-human primate models of experimental autoimmune encephalomyelitis: variations on a theme. J. Neuroimmunol. 168: 1-12.
29. Pereira, L. E., N. Onlamoon, X. Wang, R. Wang, J. Li, K. A. Reimann, F. Villinger, K. Pattanapanyasat, K. Mori, and A. A. Ansari. 2009. Preliminary in vivo efficacy studies of a recombinant rhesus anti-alpha(4)beta(7) monoclonal antibody. Cell. Immunol. 259: 165-176.
30. Kerlero de Rosbo, N., M. Hoffman, I. Mendel, I. Yust, J. Kaye, R. Bakimer, S. Flechter, O. Abramsky, R. Milo, A. Karni, and A. Ben-Nun. 1997. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur. J. Immunol. 27: 3059-3069.
31. Brok, H. P., L. Boven, M. van Meurs, N. Kerlero de Rosbo, L. Celebi-Paul, Y. S. Kap, A. Jagessar, R. Q. Hintzen, G. Keir, J. Bajramovic, et al. 2007. The human CMV-UL86 peptide 981-1003 shares a crossreactive T-cell epitope with the encephalitogenic MOG peptide 34-56, but lacks the capacity to induce EAE in rhesus monkeys. J. Neuroimmunol. 182: 135-152.
32. Brok, H. P., J. Bauer, M. Jonker, E. Blezer, S. Amor, R. E. Bontrop, J. D. Laman, and B. A. 't Hart. 2001. Non-human primate models of multiple sclerosis. Immunol. Rev. 183: 173-185.
33. Jagessar, S. A., P. A. Smith, E. Blezer, C. Delarasse, D. Pham-Dinh, J. D. Laman, J. Bauer, S. Amor, and B. 't Hart. 2008. Autoimmunity against myelin oligodendrocyte glycoprotein is dispensable for the initiation although essential for the progression of chronic encephalomyelitis in common marmosets. J. Neuropathol. Exp. Neurol. 67: 326-340.
34. Bauer, M., C. Brakebusch, C. Coisne, M. Sixt, H. Wekerle, B. Engelhardt, and R. Fässler. 2009. Beta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc. Natl. Acad. Sci. USA 106: 1920-1925.
35. Kanwar, J. R., J. E. Harrison, D. Wang, E. Leung, W. Mueller, N. Wagner, and G. W. Krissansen. 2000. Beta7 integrins contribute to demyelinating disease of the central nervous system. J. Neuroimmunol. 103: 146-152.
36. Kanwar, J. R., R. K. Kanwar, D. Wang, and G. W. Krissansen. 2000. Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunol. Cell Biol. 78: 641-645.
37. Döring, A., F. Pfeiffer, M. Meier, B. Dehouck, S. Tauber, U. Deutsch, and B. Engelhardt. 2011. TET inducible expression of the a4b7-integrin ligand MAdCAM-1 on the blood-brain barrier does not influence the immunopathogenesis of experimental autoimmune encephalomyelitis. Eur. J. Immunol. 41: 813-821.
38. Miller, D. H., D. Soon, K. T. Fernando, D. G. MacManus, G. J. Barker, T. A. Yousry, E. Fisher, P. W. O'Connor, J. T. Phillips, C. H. Polman, et al AFFIRM Investigators. 2007. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68: 1390-1401.
39. del Pilar Martin, M., P. D. Cravens, R. Winger, E. M. Frohman, M. K. Racke, T. N. Eagar, S. S. Zamvil, M. S. Weber, B. Hemmer, N. J. Karandikar, et al. 2008. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch. Neurol. 65: 1596-1603.
40. Milch, C., T. Wyant, J. Xu, W. Kent, J. R. Berger, and I. H. Fox. 2011. Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers. Gut 60(Suppl 3): A407.
41. Stüve, O., C. M. Marra, K. R. Jerome, L. Cook, P. D. Cravens, S. Cepok, E. M. Frohman, J. T. Phillips, G. Arendt, B. Hemmer, et al. 2006. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59: 743-747.
42. Jagessar, S. A., Y. S. Kap, N. Heijmans, N. van Driel, L. van Straalen, J. J. Bajramovic, H. P. Brok, E. L. Blezer, J. Bauer, J. D. Laman, and B. A. 't Hart. 2010. Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete Freund adjuvant. J. Neuropathol. Exp. Neurol. 69: 372-385.
43. 't Hart, B. A., J. D. Laman, J. Bauer, E. Blezer, Y. van Kooyk, and R. Q. Hintzen. 2004. Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol. 3: 588-597.
44. Oostendorp, R. A., and P. Dörmer. 1997. VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells. Leuk. Lymphoma 24: 423-435.
45. Pribila, J. T., A. A. Itano, K. L. Mueller, and Y. Shimizu. 2004. The alpha 1 beta 1 and alpha E beta 7 integrins define a subset of dendritic cells in peripheral lymph nodes with unique adhesive and antigen uptake properties. J. Immunol. 172: 282-291.
46. Sandborn, W. J., P. Rutgeerts, R. Enns, S. B. Hanauer, J. F. Colombel, R. Panaccione, G. D'Haens, J. Li, M. R. Rosenfeld, J. D. Kent, and P. F. Pollack. 2007. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 146: 829-838.
47. Targan, S. R., B. G. Feagan, R. N. Fedorak, B. A. Lashner, R. Panaccione, D. H. Present, M. E. Spehlmann, P. J. Rutgeerts, Z. Tulassay, M. Volfova, et al International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. 2007. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132: 1672-1683.
48. Bonig, H., A. Wundes, K. H. Chang, S. Lucas, and T. Papayannopoulou. 2008. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 111: 3439-3441.
49. Zohren, F., D. Toutzaris, V. Klärner, H. P. Hartung, B. Kieseier, and R. Haas. 2008. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111: 3893-3895.
50. Miller, D. H., O. A. Khan, W. A. Sheremata, L. D. Blumhardt, G. P. Rice, M. A. Libonati, A. J. Willmer-Hulme, C. M. Dalton, K. A. Miszkiel, and P. W. O'Connor; International Natalizumab Multiple Sclerosis Trial Group. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348: 15-23.
51. Ghosh, S., E. Goldin, F. H. Gordon, H. A. Malchow, J. Rask-Madsen, P. Rutgeerts, P. Vyhnálek, Z. Zádorová, T. Palmer, and S. Donoghue; Natalizumab Pan-European Study Group. 2003. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348: 24-32.